Abstract
learning and subsequent changes in approach/avoidance tendencies in individual patients. We assessed 23 24 PD patients on and off dopaminergic medication and 24 healthy controls (HC) performing a 24 probabilistic reinforcement learning task, while undergoing functional magnetic resonance imaging. 25 During learning, medication in PD reduced an overemphasis on negative outcomes. When patients were 26 on medication, learning rates were lower for negative (but not positive) outcomes and concurrent striatal 27 BOLD responses showed reduced prediction error sensitivity. Medication-induced shifts in negative 28 learning rates were predictive of changes in approach/avoidance choice patterns after learning, and these ON (Bayes Factor (BF) = 11.40). This is consistent with the theory that PD increases the sensitivity to 137 negative outcomes, and that dopaminergic medication remediates specifically this disease symptom. 138 Conversely, shifts in the distributions of the again and b parameters were merely anecdotal (1<BFs<2, 139 see Table S4 , and Figure S3 for individual results). For parameter comparisons based on disease 140 status, we found strong evidence for a higher b, i.e. greater exploitation, in HC compared to PD (BF = 141 16.89; see Figure S4 ). negative learning rate (aG and aL) and explore-exploit (b) parameters, for any ith subject (i= 1,…,N), pth PD 146 subject (p=1,…,N_pd), or hth HC subject (h=1,…,N_hc), as well as medication (Km) and disease (Kd) 147 difference variables for these parameters. The outermost layer represents group mean and standard deviation of 148 each parameter across all subjects, medication difference distributions and disease difference distributions. 149 Directed arrows from parents to children represent that parameters of the child are distributed according to its 150 parents; the priors of these distributions are listed to the right. Double-lined borders denote deterministic 151 variables. Continues variables are represented by circular nodes, and discrete variables by square nodes. 152 Observed variables are shaded in grey. Per subject and session, ri,t-1 is the reward received on the previous trial 153 of a particular option pair, Qi,t is the current expected value of a particular stimulus, P [S] is the probability of 154 choosing a particular stimulus in the current trial. (b) Group-level PD medication (within-subject) difference in 155 learning phase parameters from Q-learning model (associated group-level Km medication difference parameters 156 are highlighted in a). A leftward shift in the aloss distribution indicates greater learning from negative outcomes Medication in PD reduces the sensitivity of dorsal striatum to RPE 159 In the Q-learning model, the learning rate weighs the extent to which value beliefs are updated based Medication effects in dorsal striatum are specific to the processing of negative RPE
178
To disentangle the separate effects of positive and negative RPE signaling, we examined feedback-179 triggered BOLD time courses from three independent striatal masks; the caudate nucleus, putamen, 180 and nucleus accumbens (see Methods). We found a significant medication difference only in the 181 caudate nucleus, in BOLD activity associated only with negative RPE (Figure 4 ). RPE modulation 182 was greater in PD OFF compared to ON, during the interval 7.51s -10.67s after the onset of negative 183 feedback. Medication status did not alter the BOLD responses to positive RPE, indicating that 184 changes due to dopaminergic medication are specific to negative RPE signaling in the caudate 185 nucleus, the most dorsal part of the striatum. 
191
The same analysis of putamen and nucleus accumbens ROIs revealed no medication-related RPE differences
192
(see Figure S6 ). Time courses of associated BOLD percent signal change after positive and negative outcomes 193 in these striatal ROIs are presented in Figure S7 . medication in PD improved accuracy scores for "approach" trials, but decreased accuracy for "avoid" 208 trials ( Figure 5A , and see Figure S8 for HC performance Figure 5C ). In summary, these findings show that within-subject medication-related shifts in learning 234 from negative outcomes are predictive of subsequent approach/avoidance medication-related changes, 235 both in terms of behavioral accuracy and BOLD signaling in the caudate nucleus. negative outcomes became more similar to that observed in healthy controls, whereas decision-264 making volatility, i.e. the exploitation of higher-valued options, did not (see Figure S5 ).
265
The medication interaction in subsequent approach/avoidance behavior we find in the transfer We were able to link medication-dependent changes in learning from negative outcomes to 307 subsequent changes in approach/avoidance striatal activity by specifically focusing on the region that 308 showed a robust medication-dependent difference in phasic RPE modulation during learning. This 309 suggests that the caudate nucleus' processing of negative RPE in PD ON plays an important role in 310 the subsequent medication-induced shift in balance between approach and avoidance behavior.
311
Although focusing on the ventral striatum, a recent study on rats showed that increased activation in 312 the VTA-NAc pathway associated with a higher dopaminergic state was reflected in behavior by a 313 reduced sensitivity to negative outcomes (Verharen et al., 2018 Although there is moderate evidence for a higher sensitivity to negative feedback in PD OFF 328 compared to HC (see Figure S5 ), we find that the greatest disease-related difference lies in the In the learning phase, three different pairs of object stimuli (denoted as AB, CD and EF) were 413 repeatedly presented in random order. Each pair had assigned reward probabilities associated with 414 each stimulus, and participants had to learn to choose the best option of each pair based on the 415 feedback provided (see Figure 1A ). Participants were instructed to try to find the better option of a 416 pair in order to maximize reward. Feedback was either "Goed" or "Fout" text (meaning "correct" or 417 "wrong" in Dutch), indicating a payout of 10 cents for correct trials and nothing for incorrect trials.
418
Different objects were used across each fMRI session of patients, so as not to induce any familiarity 419 or reward associations with particular stimuli. In the "easiest" AB pair, the probability of receiving The mixed-effects regression on transfer phase behavior was carried out on trials in which either the 478 A or B stimulus appeared, excluding those in which both appeared together (see Figure 1B) . The these models (see Table S6 ). The learning to transfer phase accuracy correlation p-value was therefore 493 obtained from the winning aloss-only model. Individual medication differences were quantified as the 494 modes of the within-subject medication difference parameter distributions, to capture peak probability 495 densities (see Figure 2A and Group-level model).
496
Computational model 497 We fit a hierarchical Bayesian temporal difference Q-learning model to learning phase behavioral Table S3 ).
510

Subject-level model
511
The Q-learning algorithm assumes that after receiving feedback on a given trial, subjects update their The term "#$%&' ( ) − "#$%&' ( ) is the reward prediction error (RPE). Accordingly, choices 518 followed by positive feedback (r = 1) are weighted by the again learning rate parameter and choices 519 followed by negative feedback (r = 0) are weighted by the aloss learning rate parameter (0 < again, aloss 520 <1). All Q-values were initialized at 0.5 (no initial bias in value). The probability of choosing one 521 stimulus over another is described by the softmax rule:
where b is known as the inverse temperature or "explore-exploit" parameter (0 < b < 100).
524
Effectively, b is used as a weighting on the difference in value between the two options. The free 525 parameters again, aloss and b were fit for each subject individually, in a combination that maximizes 526 the probability of the actual choices made by the subject.
527
Group-level model
528
The subject-level model described above was nested inside a group-level model in a hierarchical 529 manner. All participants were assigned to one group and we fit separate group-level distributions to 530 capture the within-subject effect of medication and the across-subject effect of disease (see model 531 representation in Figure 2A ), adopting a similar group-level model to that described in (Sharp et al., 532 2016). In Figure 2A , the free parameters again and aloss are denoted as aG and aL for viewing purposes.
533
The inner box describes trial-by-trial behavior of individual subjects. The quantities ri, t-1 (reward for and Rubin, 1992). Simulations displayed in Figure S2 show adequate parameter recovery. Mean 577 group-level posterior distributions after fitting can also be seen in Figure S2 . We additionally 578 generated a number of quantities of interest from the model, including individual subjects' trial-by-579 trial RPE for inclusion in fMRI whole-brain and deconvolution analyses. 
